-DOCSTART-	O

Title	O
:	O
Hydroxychloroquine	B-I
in	O
Nonhospitalized	B-P
Adults	I-P
With	I-P
Early	I-P
COVID	I-P
-	I-P
19	I-P
:	O
A	O
Randomized	O
Trial	O
.	O

METHODS	O
:	O
Randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
conducted	O
from	O
22	O
March	O
through	O
20	O
May	O
2020	O
.	O

(	O
ClinicalTrials	O
.	O
gov	O
:	O
NCT04308668	O
)	O
.	O

Internet	O
-	O
based	O
trial	O
across	O
the	O
United	O
States	O
and	O
Canada	O
(	O
40	O
states	O
and	O
3	O
provinces	O
)	O
.	O

Symptomatic	B-P
,	I-P
nonhospitalized	I-P
adults	I-P
with	I-P
laboratory	I-P
-	I-P
confirmed	I-P
COVID	I-P
-	I-P
19	I-P
or	I-P
probable	I-P
COVID	I-P
-	I-P
19	I-P
and	I-P
high	I-P
-	I-P
risk	I-P
exposure	I-P
within	I-P
4	I-P
days	I-P
of	I-P
symptom	I-P
onset	I-P
.	O

Oral	B-I
hydroxychloroquine	I-I
(	O
800	O
mg	O
once	O
,	O
followed	O
by	O
600	O
mg	O
in	O
6	O
to	O
8	O
hours	O
,	O
then	O
600	O
mg	O
daily	O
for	O
4	O
more	O
days	O
)	O
or	O
masked	B-C
placebo	I-C
.	O

Symptoms	O
and	O
severity	O
at	O
baseline	O
and	O
then	O
at	O
days	O
3	O
,	O
5	O
,	O
10	O
,	O
and	O
14	O
using	O
a	B-O
10	I-O
-	I-O
point	I-O
visual	I-O
analogue	I-O
scale	I-O
.	O

The	O
primary	O
end	O
point	O
was	O
change	O
in	O
overall	B-O
symptom	I-O
severity	I-O
over	O
14	O
days	O
.	O

-DOCSTART-	O

Title	O
:	O
Exploring	O
an	O
Integrative	O
Therapy	O
for	O
Treating	O
COVID	O
-	O
19	O
:	O
A	O
Randomized	O
Controlled	O
Trial	O
.	O

METHODS	O
:	O
A	B-I
putative	I-I
ARDS	I-I
-	I-I
suppressing	I-I
drug	I-I
Keguan	I-I
-	I-I
1	I-I
was	O
first	O
developed	O
and	O
then	O
evaluated	O
by	O
a	O
randomized	O
,	O
controlled	O
two	O
-	O
arm	O
trial	O
.	O

The	O
two	O
arms	O
of	O
the	O
trial	O
consist	O
of	O
a	O
control	O
therapy	O
(	O
alpha	B-C
interferon	I-C
inhalation	I-C
,	O
50	O
g	O
twice	O
daily	O
;	O
and	O
lopinavir	B-C
/	O
ritonavir	B-C
,	O
400	O
and	O
100	O
mg	O
twice	O
daily	O
,	O
respectively	O
)	O
and	O
a	O
testing	O
therapy	O
(	O
control	O
therapy	O
plus	O
Keguan	B-I
-	I-I
1	I-I
19	O
.	O
4	O
g	O
twice	O
daily	O
)	O
by	O
random	O
number	O
table	O
at	O
1	O
:	O
1	O
ratio	O
with	O
24	O
cases	O
each	O
group	O
.	O

After	O
2	O
-	O
week	O
treatment	O
,	O
adverse	B-O
events	I-O
,	O
time	B-O
to	I-O
fever	I-O
resolution	I-O
,	O
ARDS	B-O
development	I-O
,	O
and	O
lung	B-O
injury	I-O
on	O
newly	B-P
diagnosed	I-P
COVID	I-P
-	I-P
19	I-P
patients	I-P
were	O
assessed	O
.	O

-DOCSTART-	O

Title	O
:	O
Dexamethasone	B-I
in	O
Hospitalized	B-P
Patients	I-P
with	I-P
Covid	I-P
-	I-P
19	I-P
.	O

METHODS	O
:	O
In	O
this	O
controlled	O
,	O
open	O
-	O
label	O
trial	O
comparing	O
a	O
range	O
of	O
possible	O
treatments	O
in	O
patients	B-P
who	I-P
were	I-P
hospitalized	I-P
with	I-P
Covid	I-P
-	I-P
19	I-P
,	O
we	O
randomly	O
assigned	O
patients	O
to	O
receive	O
oral	B-I
or	O
intravenous	B-I
dexamethasone	I-I
(	O
at	O
a	O
dose	O
of	O
6	O
mg	O
once	O
daily	O
)	O
for	O
up	O
to	O
10	O
days	O
or	O
to	O
receive	O
usual	B-C
care	I-C
alone	I-C
.	O

The	O
primary	O
outcome	O
was	O
28	B-O
-	I-O
day	I-O
mortality	I-O
.	O

Here	O
,	O
we	O
report	O
the	O
final	O
results	O
of	O
this	O
assessment	O
.	O

-DOCSTART-	O

Title	O
:	O
Hydroxychloroquine	B-I
with	O
or	O
without	O
Azithromycin	B-I
in	O
Mild	O
-	O
to	O
-	O
Moderate	O
Covid	O
-	O
19	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
multicenter	O
,	O
randomized	O
,	O
open	O
-	O
label	O
,	O
three	O
-	O
group	O
,	O
controlled	O
trial	O
involving	O
hospitalized	B-P
patients	I-P
with	I-P
suspected	I-P
or	I-P
confirmed	I-P
Covid	I-P
-	I-P
19	I-P
who	I-P
were	I-P
receiving	I-P
either	I-P
no	I-P
supplemental	I-P
oxygen	I-P
or	I-P
a	I-P
maximum	I-P
of	I-P
4	I-P
liters	I-P
per	I-P
minute	I-P
of	I-P
supplemental	I-P
oxygen	I-P
.	O

Patients	O
were	O
randomly	O
assigned	O
in	O
a	O
1:1:1	O
ratio	O
to	O
receive	O
standard	B-C
care	I-C
,	O
standard	B-I
care	I-I
plus	O
hydroxychloroquine	B-I
at	O
a	O
dose	O
of	O
400	O
mg	O
twice	O
daily	O
,	O
or	O
standard	B-I
care	I-I
plus	O
hydroxychloroquine	B-I
at	O
a	O
dose	O
of	O
400	O
mg	O
twice	O
daily	O
plus	O
azithromycin	B-I
at	O
a	O
dose	O
of	O
500	O
mg	O
once	O
daily	O
for	O
7	O
days	O
.	O

The	O
primary	O
outcome	O
was	O
clinical	B-O
status	I-O
at	O
15	O
days	O
as	O
assessed	O
with	O
the	O
use	O
of	O
a	B-O
seven	I-O
-	I-O
level	I-O
ordinal	I-O
scale	I-O
(	O
with	O
levels	O
ranging	O
from	O
one	O
to	O
seven	O
and	O
higher	O
scores	O
indicating	O
a	O
worse	O
condition	O
)	O
in	O
the	O
modified	O
intention	O
-	O
to	O
-	O
treat	O
population	O
(	O
patients	O
with	O
a	O
confirmed	O
diagnosis	O
of	O
Covid	O
-	O
19	O
)	O
.	O

Safety	B-O
was	O
also	O
assessed	O
.	O

-DOCSTART-	O

Title	O
:	O
Historically	O
controlled	O
comparison	O
of	O
glucocorticoids	B-I
with	O
or	O
without	O
tocilizumab	B-I
versus	O
supportive	B-C
care	I-C
only	I-C
in	O
patients	B-P
with	I-P
COVID	I-P
-	I-P
19	I-P
-	I-P
associated	I-P
cytokine	I-P
storm	I-P
syndrome	I-P
:	O
results	O
of	O
the	O
CHIC	O
study	O
.	O

METHODS	O
:	O
From	O
1	O
April	O
2020	O
,	O
patients	B-P
with	I-P
COVID	I-P
-	I-P
19	I-P
-	I-P
associated	I-P
CSS	I-P
,	I-P
defined	I-P
as	I-P
rapid	I-P
respiratory	I-P
deterioration	I-P
plus	I-P
at	I-P
least	I-P
two	I-P
out	I-P
of	I-P
three	I-P
biomarkers	I-P
with	I-P
important	I-P
elevations	I-P
(	I-P
C	I-P
-	I-P
reactive	I-P
protein	I-P
>	I-P
100	I-P
mg	I-P
/	I-P
L	I-P
;	I-P
ferritin	I-P
>	I-P
900	I-P
g	I-P
/	I-P
L	I-P
;	I-P
D	I-P
-	I-P
dimer	I-P
>	I-P
1500	I-P
g	I-P
/	I-P
L	I-P
)	I-P
,	O
received	O
high	B-I
-	I-I
dose	I-I
intravenous	I-I
methylprednisolone	I-I
for	O
5	O
consecutive	O
days	O
(	O
250	O
mg	O
on	O
day	O
1	O
followed	O
by	O
80	O
mg	O
on	O
days	O
2	O
-	O
5	O
)	O
.	O

If	O
the	O
respiratory	O
condition	O
had	O
not	O
improved	O
sufficiently	O
(	O
in	O
43	O
%	O
)	O
,	O
the	B-I
interleukin	I-I
-	I-I
6	I-I
receptor	I-I
blocker	I-I
tocilizumab	I-I
(	O
8	O
mg	O
/	O
kg	O
body	O
weight	O
,	O
single	O
infusion	O
)	O
was	O
added	O
on	O
or	O
after	O
day	O
2	O
.	O

Control	O
patients	O
with	O
COVID	O
-	O
19	O
-	O
associated	O
CSS	O
(	O
same	O
definition	O
)	O
were	O
retrospectively	O
sampled	O
from	O
the	O
pool	O
of	O
patients	O
(	O
n=350	O
)	O
admitted	O
between	O
7	O
March	O
and	O
31	O
March	O
,	O
and	O
matched	O
one	O
to	O
one	O
to	O
treated	O
patients	O
on	O
sex	O
and	O
age	O
.	O

The	O
primary	O
outcome	O
was	O
?2	O
stages	O
of	O
improvement	O
on	O
a	B-O
7	I-O
-	I-O
item	I-O
WHO	I-O
-	I-O
endorsed	I-O
scale	I-O
for	O
trials	O
in	O
patients	B-P
with	I-P
severe	I-P
influenza	I-P
pneumonia	I-P
,	O
or	O
discharge	B-O
from	I-O
the	I-O
hospital	I-O
.	O

Secondary	O
outcomes	O
were	O
hospital	B-O
mortality	I-O
and	O
mechanical	B-O
ventilation	I-O
.	O

-DOCSTART-	O

Title	O
:	O
SARS	O
-	O
CoV	O
-	O
2	O
clearance	O
in	O
COVID	B-P
-	I-P
19	I-P
patients	I-P
with	O
Novaferon	B-I
treatment	O
:	O
A	O
randomized	O
,	O
open	O
-	O
label	O
,	O
parallel	O
-	O
group	O
trial	O
.	O

METHODS	O
:	O
In	O
the	O
laboratory	O
,	O
Novaferon	B-I
'	O
s	O
inhibition	O
of	O
viral	O
replication	O
in	O
cells	O
infected	O
with	O
SARS	O
-	O
CoV	O
-	O
2	O
,	O
and	O
prevention	O
of	O
SARS	O
-	O
CoV	O
-	O
2	O
entry	O
into	O
healthy	O
cells	O
was	O
determined	O
.	O

Antiviral	O
effects	O
of	O
Novaferon	B-I
in	O
COVID	B-P
-	I-P
19	I-P
patients	I-P
with	O
treatment	O
of	O
Novaferon	B-I
,	O
Novaferon	B-I
plus	O
Lopinavir	B-I
/	O
Ritonavir	B-I
,	O
or	O
Lopinavir	B-I
/	O
Ritonavir	B-I
were	O
evaluated	O
.	O

The	O
primary	O
endpoint	O
was	O
the	B-O
SARS	I-O
-	I-O
CoV	I-O
-	I-O
2	I-O
clearance	I-O
rates	I-O
on	O
day	O
six	O
of	O
treatment	O
,	O
and	O
the	O
secondary	O
endpoint	O
was	O
the	B-O
time	I-O
to	I-O
SARS	I-O
-	I-O
CoV	I-O
-	I-O
2	I-O
clearance	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Pakistan	O
Randomized	O
and	O
Observational	O
Trial	O
to	O
Evaluate	O
Coronavirus	O
Treatment	O
(	O
PROTECT	O
)	O
of	O
Hydroxychloroquine	B-I
,	O
Oseltamivir	B-I
and	O
Azithromycin	B-I
to	O
treat	O
newly	B-P
diagnosed	I-P
patients	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
infection	I-P
who	I-P
have	I-P
no	I-P
comorbidities	I-P
like	I-P
diabetes	I-P
mellitus	I-P
:	O
A	O
structured	O
summary	O
of	O
a	O
study	O
protocol	O
for	O
a	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
An	O
adaptive	O
design	O
,	O
set	O
within	O
a	O
comprehensive	O
cohort	O
study	O
,	O
to	O
permit	O
flexibility	O
in	O
this	O
fast	O
-	O
changing	O
clinical	O
and	O
public	O
health	O
scenario	O
.	O

The	O
randomized	O
study	O
will	O
be	O
a	O
multicenter	O
,	O
multiarm	O
,	O
multistage	O
,	O
randomized	O
controlled	O
trial	O
with	O
a	O
parallel	O
design	O
.	O

An	O
observation	O
only	O
cohort	O
will	O
emerge	O
from	O
those	O
not	O
consenting	O
to	O
randomization	O
.	O

Eligible	O
will	O
be	O
newly	B-P
diagnosed	I-P
patients	I-P
,	I-P
either	I-P
hospitalized	I-P
or	I-P
in	I-P
self	I-P
-	I-P
isolation	I-P
,	I-P
without	I-P
any	I-P
comorbidities	I-P
or	I-P
with	I-P
controlled	I-P
chronic	I-P
medical	I-P
conditions	I-P
like	I-P
diabetes	I-P
mellitus	I-P
and	I-P
hypertension	I-P
.	O

Participants	O
of	O
any	O
gender	O
or	O
age	O
group	O
having	O
tested	O
positive	O
for	O
COVID	O
-	O
19	O
on	O
Real	O
-	O
Time	O
qRT	O
-	O
PCR	O
(	O
Quantitative	O
Reverse	O
Transcription	O
PCR	O
)	O
will	O
be	O
invited	O
to	O
take	O
part	O
in	O
study	O
at	O
twelve	O
centers	O
across	O
eight	O
cities	O
in	O
Pakistan	O
.	O

Those	O
pregnant	O
or	O
lactating	O
,	O
severely	O
dyspneic	O
or	O
with	O
respiratory	O
distress	O
,	O
already	O
undergoing	O
treatment	O
,	O
and	O
with	O
serious	O
comorbidities	O
like	O
liver	O
or	O
kidney	O
failure	O
will	O
be	O
excluded	O
.	O

METHODS	O
:	O
Participants	O
will	O
be	O
randomized	O
,	O
maintaining	O
concealment	O
of	O
allocation	O
sequence	O
,	O
using	O
a	O
computer	O
-	O
generated	O
random	O
number	O
list	O
of	O
variable	O
block	O
size	O
into	O
multiple	O
intervention	O
groups	O
in	O
the	O
allocation	O
ratio	O
of	O
1	O
:	O
1	O
for	O
all	O
groups	O
.	O

This	O
is	O
an	O
open	O
label	O
study	O
,	O
neither	O
physician	O
nor	O
participants	O
will	O
be	O
blinded	O
.	O

This	O
is	O
an	O
adaptive	O
design	O
and	O
parameters	O
for	O
formal	O
sample	O
size	O
calculation	O
in	O
a	O
new	O
disease	O
of	O
a	O
previously	O
unknown	O
virus	O
are	O
not	O
available	O
.	O

Thus	O
,	O
the	O
final	O
sample	O
size	O
will	O
be	O
subjected	O
to	O
periodic	O
reviews	O
at	O
each	O
stage	O
of	O
adaptive	O
design	O
and	O
subsequent	O
advice	O
of	O
National	O
Data	O
Safety	O
&	O
Management	O
Board	O
(	O
NDSMB	O
)	O
notified	O
by	O
Drug	O
Regulatory	O
Authority	O
of	O
Pakistan	O
.	O

Protocol	O
Version	O
1	O
.	O
7	O
dated	O
July	O
5	O
,	O
2020	O
.	O

By	O
July	O
03	O
,	O
2020	O
,	O
the	O
trial	O
had	O
recruited	O
a	O
total	O
of	O
about	O
470	O
participants	O
across	O
12	O
centers	O
after	O
approval	O
from	O
the	O
National	O
Bioethics	O
Committee	O
and	O
Drug	O
Regulatory	O
Authority	O
of	O
Pakistan	O
.	O

Recruitment	O
started	O
on	O
April	O
20	O
,	O
2020	O
.	O

The	O
recruitment	O
is	O
expected	O
to	O
continue	O
for	O
at	O
least	O
three	O
months	O
subject	O
to	O
review	O
by	O
the	O
National	O
Data	O
Safety	O
and	O
Management	O
Board	O
(	O
NDSMB	O
)	O
notified	O
by	O
Drug	O
Regulatory	O
Authority	O
of	O
Pakistan	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
of	O
Huoxiang	B-I
Zhengqi	I-I
dropping	I-I
pills	I-I
and	O
Lianhua	B-I
Qingwen	I-I
granules	I-I
in	O
treatment	O
of	O
COVID	O
-	O
19	O
:	O
A	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
283	I-P
patients	I-P
participated	O
in	O
this	O
clinical	O
trial	O
,	O
and	O
participants	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
1	O
)	O
Huoxiang	B-I
Zhengqi	I-I
dropping	I-I
pills	I-I
and	O
Lianhua	B-I
Qingwen	I-I
granules	I-I
or	O
2	O
)	O
Linahua	B-I
granules	I-I
,	O
both	O
combined	O
with	O
western	B-I
medicine	I-I
,	O
or	O
3	O
)	O
western	B-C
medicine	I-C
alone	I-C
for	O
14	O
days	O
.	O

At	O
the	O
end	O
of	O
the	O
trial	O
,	O
the	B-O
improvement	I-O
and	O
resolution	B-O
rates	I-O
of	I-O
clinical	I-O
symptoms	I-O
and	O
the	B-O
rate	I-O
of	I-O
patients	I-O
who	I-O
progressed	I-O
to	I-O
severe	I-O
disease	I-O
status	I-O
were	O
evaluated	O
.	O

-DOCSTART-	O

Title	O
:	O
Auxora	B-I
versus	O
standard	B-C
of	I-C
care	I-C
for	O
the	O
treatment	O
of	O
severe	O
or	O
critical	O
COVID	O
-	O
19	O
pneumonia	O
:	O
results	O
from	O
a	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
A	O
randomized	O
,	O
controlled	O
,	O
open	O
-	O
label	O
study	O
of	O
Auxora	B-I
was	O
conducted	O
in	O
adults	B-P
with	I-P
severe	I-P
or	I-P
critical	I-P
COVID	I-P
-	I-P
19	I-P
pneumonia	I-P
.	O

Patients	O
were	O
randomized	O
2	O
:	O
1	O
to	O
receive	O
three	B-I
doses	I-I
of	I-I
once	I-I
-	I-I
daily	I-I
Auxora	I-I
versus	O
standard	B-C
of	I-C
care	I-C
(	I-C
SOC	I-C
)	I-C
alone	I-C
.	O

The	O
primary	O
objective	O
was	O
to	O
assess	O
the	B-O
safety	I-O
and	O
tolerability	B-O
of	O
Auxora	B-I
.	O

Following	O
FDA	O
guidance	O
,	O
study	O
enrollment	O
was	O
halted	O
early	O
to	O
allow	O
for	O
transition	O
to	O
a	O
randomized	O
,	O
blinded	O
,	O
placebo	O
-	O
controlled	O
study	O
.	O

-DOCSTART-	O

Title	O
:	O
Treatment	O
of	O
severe	O
COVID	O
-	O
19	O
with	O
human	B-I
umbilical	I-I
cord	I-I
mesenchymal	I-I
stem	I-I
cells	I-I
.	O

METHODS	O
:	O
Patients	B-P
with	I-P
severe	I-P
COVID	I-P
-	I-P
19	I-P
were	O
randomly	O
divided	O
into	O
2	O
groups	O
:	O
the	B-C
standard	I-C
treatment	I-C
group	O
and	O
the	B-I
standard	I-I
treatment	I-I
plus	O
hUC	B-I
-	I-I
MSC	I-I
infusion	I-I
group	O
.	O

The	B-O
incidence	I-O
of	I-O
progression	I-O
from	I-O
severe	I-O
to	I-O
critical	I-O
illness	I-O
,	O
28	B-O
-	I-O
day	I-O
mortality	I-O
,	O
clinical	B-O
symptom	I-O
improvement	I-O
,	O
time	B-O
to	I-O
clinical	I-O
symptom	I-O
improvement	I-O
,	O
hematologic	B-O
indicators	I-O
including	I-O
C	I-O
-	I-O
reactive	I-O
protein	I-O
,	O
lymphocyte	B-O
number	I-O
,	O
and	O
interleukin	B-O
6	I-O
,	O
and	O
imaging	B-O
changes	I-O
were	O
observed	O
and	O
compared	O
between	O
the	O
two	O
groups	O
.	O

-DOCSTART-	O

Title	O
:	O
Sofosbuvir	B-I
and	O
daclatasvir	B-I
compared	O
with	O
standard	B-C
of	I-C
care	I-C
in	O
the	O
treatment	O
of	O
patients	B-P
admitted	I-P
to	I-P
hospital	I-P
with	I-P
moderate	I-P
or	I-P
severe	I-P
coronavirus	I-P
infection	I-P
(	I-P
COVID	I-P
-	I-P
19	I-P
)	I-P
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
This	O
was	O
an	O
open	O
-	O
label	O
,	O
multicentre	O
,	O
randomized	O
controlled	O
clinical	O
trial	O
in	O
adults	B-P
with	I-P
moderate	I-P
or	I-P
severe	I-P
COVID	I-P
-	I-P
19	I-P
admitted	I-P
to	I-P
four	I-P
university	I-P
hospitals	I-P
in	I-P
Iran	I-P
.	O

Patients	O
were	O
randomized	O
into	O
a	O
treatment	O
arm	O
receiving	O
sofosbuvir	B-I
and	O
daclatasvir	B-I
plus	O
standard	B-I
care	I-I
,	O
or	O
a	O
control	O
arm	O
receiving	O
standard	B-C
care	I-C
alone	I-C
.	O

The	O
primary	O
endpoint	O
was	O
clinical	B-O
recovery	I-O
within	O
14	O
days	O
of	O
treatment	O
.	O

The	O
study	O
is	O
registered	O
with	O
IRCT	O
.	O
ir	O
under	O
registration	O
number	O
IRCT20200128046294N2	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
impact	O
of	O
sofosbuvir	B-I
/	O
daclatasvir	B-I
or	O
ribavirin	B-I
in	O
patients	B-P
with	I-P
severe	I-P
COVID	I-P
-	I-P
19	I-P
.	O

METHODS	O
:	O
Patients	B-P
with	I-P
a	I-P
positive	I-P
nasopharyngeal	I-P
swab	I-P
for	I-P
SARS	I-P
-	I-P
CoV	I-P
-	I-P
2	I-P
on	I-P
RT	I-P
-	I-P
PCR	I-P
or	I-P
bilateral	I-P
multi	I-P
-	I-P
lobar	I-P
ground	I-P
-	I-P
glass	I-P
opacity	I-P
on	I-P
their	I-P
chest	I-P
CT	I-P
and	I-P
signs	I-P
of	I-P
severe	I-P
COVID	I-P
-	I-P
19	I-P
were	O
included	O
.	O

Subjects	O
were	O
divided	O
into	O
two	O
arms	O
with	O
one	O
arm	O
receiving	O
ribavirin	B-I
and	O
the	O
other	O
receiving	O
sofosbuvir	B-I
/	O
daclatasvir	B-I
.	O

All	O
participants	O
also	O
received	O
the	B-I
recommended	I-I
national	I-I
standard	I-I
treatment	I-I
which	O
,	O
at	O
that	O
time	O
,	O
was	O
lopinavir	B-I
/	O
ritonavir	B-I
and	O
single	B-I
-	I-I
dose	I-I
hydroxychloroquine	I-I
.	O

The	O
primary	O
endpoint	O
was	O
time	B-O
from	I-O
starting	I-O
the	I-O
medication	I-O
until	I-O
discharge	I-O
from	I-O
hospital	I-O
with	O
secondary	O
endpoints	O
of	O
duration	B-O
of	I-O
ICU	I-O
stay	I-O
and	O
mortality	B-O
.	O

-DOCSTART-	O

Title	O
:	O
Anti	B-I
-	I-I
Thrombotic	I-I
Therapy	I-I
to	O
Ameliorate	O
Complications	O
of	O
COVID	O
-	O
19	O
(	O
ATTACC	O
)	O
:	O
Study	O
design	O
and	O
methodology	O
for	O
an	O
international	O
,	O
adaptive	O
Bayesian	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
An	O
international	O
,	O
open	O
-	O
label	O
,	O
adaptive	O
randomized	O
controlled	O
trial	O
.	O

Using	O
a	O
Bayesian	O
framework	O
,	O
the	O
trial	O
will	O
declare	O
results	O
as	O
soon	O
as	O
pre	O
-	O
specified	O
posterior	O
probabilities	O
for	O
superiority	O
,	O
futility	O
,	O
or	O
harm	O
are	O
reached	O
.	O

The	O
trial	O
uses	O
response	O
-	O
adaptive	O
randomization	O
to	O
maximize	O
the	O
probability	O
that	O
patients	O
will	O
receive	O
the	O
more	O
beneficial	O
treatment	O
approach	O
,	O
as	O
treatment	O
effect	O
information	O
accumulates	O
within	O
the	O
trial	O
.	O

By	O
leveraging	O
a	O
common	O
data	O
safety	O
monitoring	O
board	O
and	O
pooling	O
data	O
with	O
a	O
second	O
similar	O
international	O
Bayesian	O
adaptive	O
trial	O
(	O
REMAP	O
-	O
COVID	O
anticoagulation	O
domain	O
)	O
,	O
treatment	O
efficacy	O
and	O
safety	O
will	O
be	O
evaluated	O
as	O
efficiently	O
as	O
possible	O
.	O

The	O
primary	O
outcome	O
is	O
an	O
ordinal	O
endpoint	O
with	O
three	O
possible	O
outcomes	O
based	O
on	O
the	B-O
worst	I-O
status	I-O
of	I-O
each	I-O
patient	I-O
through	O
day	O
30	O
:	O
no	B-O
requirement	I-O
for	I-O
invasive	I-O
mechanical	I-O
ventilation	I-O
,	O
invasive	B-O
mechanical	I-O
ventilation	I-O
or	O
death	B-O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
Remdesivir	B-I
vs	O
Standard	B-C
Care	I-C
on	O
Clinical	O
Status	O
at	O
11	O
Days	O
in	O
Patients	B-P
With	I-P
Moderate	I-P
COVID	I-P
-	I-P
19	I-P
:	O
A	O
Randomized	O
Clinical	O
Trial	O
.	O

METHODS	O
:	O
Randomized	O
,	O
open	O
-	O
label	O
trial	O
of	O
hospitalized	B-P
patients	I-P
with	I-P
confirmed	I-P
severe	I-P
acute	I-P
respiratory	I-P
syndrome	I-P
coronavirus	I-P
2	I-P
(	I-P
SARS	I-P
-	I-P
CoV	I-P
-	I-P
2	I-P
)	I-P
infection	I-P
and	I-P
moderate	I-P
COVID	I-P
-	I-P
19	I-P
pneumonia	I-P
(	I-P
pulmonary	I-P
infiltrates	I-P
and	I-P
room	I-P
-	I-P
air	I-P
oxygen	I-P
saturation	I-P
>	I-P
94	I-P
%	I-P
)	I-P
enrolled	I-P
from	I-P
March	I-P
15	I-P
through	I-P
April	I-P
18	I-P
,	I-P
2020	I-P
,	I-P
at	I-P
105	I-P
hospitals	I-P
in	I-P
the	I-P
United	I-P
States	I-P
,	I-P
Europe	I-P
,	I-P
and	I-P
Asia	I-P
.	O

The	O
date	O
of	O
final	O
follow	O
-	O
up	O
was	O
May	O
20	O
,	O
2020	O
.	O

Patients	O
were	O
randomized	O
in	O
a	O
1:1:1	O
ratio	O
to	O
receive	O
a	B-I
10	I-I
-	I-I
day	I-I
course	I-I
of	I-I
remdesivir	I-I
(	O
n	O
=	O
197	O
)	O
,	O
a	B-I
5	I-I
-	I-I
day	I-I
course	I-I
of	I-I
remdesivir	I-I
(	O
n	O
=	O
199	O
)	O
,	O
or	O
standard	B-C
care	I-C
(	O
n	O
=	O
200	O
)	O
.	O

Remdesivir	B-I
was	O
dosed	O
intravenously	O
at	O
200	O
mg	O
on	O
day	O
1	O
followed	O
by	O
100	O
mg	O
/	O
d	O
.	O

The	O
primary	O
end	O
point	O
was	O
clinical	B-O
status	I-O
on	O
day	O
11	O
on	O
a	B-O
7	I-O
-	I-O
point	I-O
ordinal	I-O
scale	I-O
ranging	O
from	O
death	O
(	O
category	O
1	O
)	O
to	O
discharged	O
(	O
category	O
7	O
)	O
.	O

Differences	O
between	O
remdesivir	B-I
treatment	I-I
groups	O
and	O
standard	B-C
care	I-C
were	O
calculated	O
using	O
proportional	O
odds	O
models	O
and	O
expressed	O
as	O
odds	O
ratios	O
.	O

An	O
odds	O
ratio	O
greater	O
than	O
1	O
indicates	O
difference	O
in	O
clinical	O
status	O
distribution	O
toward	O
category	O
7	O
for	O
the	B-I
remdesivir	I-I
group	O
vs	O
the	B-C
standard	I-C
care	I-C
group	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
Hydrocortisone	B-I
on	O
21	O
-	O
Day	O
Mortality	O
or	O
Respiratory	O
Support	O
Among	O
Critically	B-P
Ill	I-P
Patients	I-P
With	I-P
COVID	I-P
-	I-P
19	I-P
:	O
A	O
Randomized	O
Clinical	O
Trial	O
.	O

METHODS	O
:	O
Multicenter	O
randomized	O
double	O
-	O
blind	O
sequential	O
trial	O
conducted	O
in	O
France	O
,	O
with	O
interim	O
analyses	O
planned	O
every	O
50	O
patients	O
.	O

Patients	B-P
admitted	I-P
to	I-P
the	I-P
intensive	I-P
care	I-P
unit	I-P
(	I-P
ICU	I-P
)	I-P
for	I-P
COVID	I-P
-	I-P
19	I-P
-	I-P
related	I-P
acute	I-P
respiratory	I-P
failure	I-P
were	O
enrolled	O
from	O
March	O
7	O
to	O
June	O
1	O
,	O
2020	O
,	O
with	O
last	O
follow	O
-	O
up	O
on	O
June	O
29	O
,	O
2020	O
.	O

The	O
study	O
intended	O
to	O
enroll	O
290	O
patients	O
but	O
was	O
stopped	O
early	O
following	O
the	O
recommendation	O
of	O
the	O
data	O
and	O
safety	O
monitoring	O
board	O
.	O

Patients	O
were	O
randomized	O
to	O
receive	O
low	B-I
-	I-I
dose	I-I
hydrocortisone	I-I
(	O
n	O
=	O
76	O
)	O
or	O
placebo	B-C
(	O
n	O
=	O
73	O
)	O
.	O

The	O
primary	O
outcome	O
,	O
treatment	B-O
failure	I-O
on	O
day	O
21	O
,	O
was	O
defined	O
as	O
death	B-O
or	O
persistent	B-O
dependency	I-O
on	I-O
mechanical	I-O
ventilation	I-O
or	O
high	B-O
-	I-O
flow	I-O
oxygen	I-O
therapy	I-O
.	O

Prespecified	O
secondary	O
outcomes	O
included	O
the	B-O
need	I-O
for	I-O
tracheal	I-O
intubation	I-O
(	O
among	O
patients	O
not	O
intubated	O
at	O
baseline	O
)	O
;	O
cumulative	B-O
incidences	I-O
(	I-O
until	I-O
day	I-O
21	I-O
)	I-O
of	I-O
prone	I-O
position	I-O
sessions	I-O
,	O
extracorporeal	B-O
membrane	I-O
oxygenation	I-O
,	O
and	O
inhaled	B-O
nitric	I-O
oxide	I-O
;	O
Pao2	B-O
:	I-O
Fio2	I-O
ratio	I-O
measured	O
daily	O
from	O
day	O
1	O
to	O
day	O
7	O
,	O
then	O
on	O
days	O
14	O
and	O
21	O
;	O
and	O
the	B-O
proportion	I-O
of	I-O
patients	I-O
with	I-O
secondary	I-O
infections	I-O
during	O
their	O
ICU	O
stay	O
.	O
